Head-to-head · WeighScore
AM Rx vs ClickSlim
The verdict
ClickSlim takes it — 49.9/100 to 49.6/100, but only just.
ClickSlim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Wyoming-registered telehealth selling compounded tirzepatide and NAD+ on introductory rates that step up after the first month, with no published state list. AM Rx is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AM Rx | ClickSlim |
|---|---|---|
| WeighScore | 49.6/100 | 49.9/100 |
| Grade | C | C |
| Scorecard rank | #491 | #490 |
| Semaglutide | $151/mo (quarterly plan, plus a separate fee, compounded) | Not disclosed |
| Tirzepatide | Not disclosed | $349/mo (compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #491 · C
Strengths
- Insurance coordination for brand-name GLP-1s — as low as $25/mo
- All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
- HSA and FSA accepted
- Video visits available with providers averaging 10+ years' experience
- Compounded semaglutide from $151/mo on the quarterly plan
Where it loses points
- Active FTC/DOJ lawsuit over deceptive billing and subscription practices
- Novo Nordisk false-advertising lawsuit (Aug 2025)
- Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
- Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #490 · C
Strengths
- Both the introductory and the ongoing price are published, so the step-up is visible before you buy
- States plainly that it is not a pharmacy or a drug manufacturer and that medication is dispensed by a licensed third party
- Text support line published with stated hours
- LegitScript certification verified against the issued seal, not just the badge
Where it loses points
- Its own NAD+ product card is labelled CONTAINS TIRZEPATIDE, which contradicts the product it is selling
- No state list is published; the site says only that services are available in most States
- Prices are among the highest in the category, at $349 ongoing for tirzepatide
- Registered at a Sheridan, Wyoming suite address commonly used as a mail-forwarding and registered-agent address
- Terms set arbitration in San Diego under California law while the company address is in Wyoming
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.